San Diego: ApoE, Aβ, and AD—Strengthening the Synaptic Connection
At SfN, several presentations and posters focused on links between synapse health and apolipoprotein E (ApoE), a major risk factor for late-onset AD...
6397 RESULTS
Sort By:
At SfN, several presentations and posters focused on links between synapse health and apolipoprotein E (ApoE), a major risk factor for late-onset AD...
The locus ceruleus has only recently begun to draw wider attention among neurodegeneration scientists...
Despite decades of research, it is still not clear how apolipoprotein E ties in with AD etiology...
Shoring up insulin responses is a tried-and-true strategy for helping people manage type 2 diabetes (T2D), but could it also prevent or delay Alzheimer’s disease?...
Move over, mice; there are now one, and possibly two, models for amyotrophic lateral sclerosis in man’s best friend...
What causes Aβ to go rogue in Alzheimer’s disease?...
Progranulin, a raw form of granulin (GRN), landed center stage of neurodegeneration research four years ago...
If posters at the Society for Neuroscience (SfN) meeting and a recent publication are any indication, the field is poised to discover a wealth of clues to TDP-43 function...
Mirroring a trend in amyloid-β research, work on the tau protein seems to be moving from tangles toward that infamous “O” word—oligomers...
London: Europe-U.S. Regulators Mull Prevention Trial in Familial AD London: What, No Argument? Speakers Agree on Trials for Familial AD London: What Regulators Say About Trials in Familial AD London: Families Talk About Treatment Trials In November 2010,
Unusually for this conference, the buzz was less about the latest hot research and more about the chilling funding scenario unfolding at the NIA...
Autosomal-dominant Alzheimer's and Huntington's disease family representatives spoke or showed videos about treatment trials...
Eight EMA officials and nine FDA officials took part in a discussion about preclinical trials in autosomal-dominant AD...
Part 2 of Alzforum’s coverage continues with what scientists from inside and outside DIAN said about the prospect of such pre-symptomatic trials...
The charge of this meeting was to begin a dialogue toward the shared goal of offering therapeutic treatment and prevention trials to families with autosomal-dominant AD...
No filters selected